Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
EWTX Edgewise Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: EWTX
Price (delayed)
$14.49
Market cap
$1.52B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.55
Enterprise value
$1.48B
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need.
Highlights
Edgewise Therapeutics's debt has decreased by 13% YoY and by 3.8% from the previous quarter
The quick ratio has contracted by 43% YoY but it has grown by 4.9% from the previous quarter
The net income is down by 38% year-on-year and by 9% since the previous quarter
Edgewise Therapeutics's equity has decreased by 20% YoY and by 6% from the previous quarter
Key stats
What are the main financial stats of EWTX
Market
Valuations
Earnings
Shares outstanding
105.2M
Market cap
$1.52B
Enterprise value
$1.48B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.21
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$170.04M
Net income
-$146.09M
EBIT
-$146.09M
EBITDA
-$143.77M
Free cash flow
-$119.36M
Per share
Balance sheet
Liquidity
EPS
-$1.55
EPS diluted
-$1.55
Free cash flow per share
-$1.25
Book value per share
$4.51
Revenue per share
$0
TBVPS
$4.78
Total assets
$454.39M
Total liabilities
$24.67M
Debt
$4.56M
Equity
$429.72M
Working capital
$422.06M
Debt to equity
0.01
Current ratio
20.99
Quick ratio
20.67
Net debt/EBITDA
0.32
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-29.5%
Return on equity
-30.9%
Return on invested capital
-33.5%
Return on capital employed
-33.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EWTX stock price
How has the Edgewise Therapeutics stock price performed over time
Intraday
-2.36%
1 week
3.57%
1 month
-14.31%
1 year
-16.92%
YTD
-45.73%
QTD
-34.14%
Financial performance
How have Edgewise Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$170.04M
Net income
-$146.09M
Gross margin
N/A
Net margin
N/A
The net income is down by 38% year-on-year and by 9% since the previous quarter
The operating income has declined by 38% year-on-year and by 7% since the previous quarter
Price vs fundamentals
How does EWTX's price correlate with its fundamentals
Growth
What is Edgewise Therapeutics's growth rate over time
Valuation
What is Edgewise Therapeutics stock price valuation
P/E
N/A
P/B
3.21
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 7% QoQ
The P/B is 32% less than the last 4 quarters average of 4.7 but 11% more than the 5-year quarterly average of 2.9
Edgewise Therapeutics's equity has decreased by 20% YoY and by 6% from the previous quarter
Efficiency
How efficient is Edgewise Therapeutics business performance
EWTX's ROIC is down by 17% QoQ and by 4% YoY
EWTX's ROA is down by 15% since the previous quarter and by 7% year-on-year
Edgewise Therapeutics's ROE has decreased by 15% from the previous quarter and by 6% YoY
Dividends
What is EWTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EWTX.
Financial health
How did Edgewise Therapeutics financials performed over time
The quick ratio has contracted by 43% YoY but it has grown by 4.9% from the previous quarter
EWTX's current ratio is down by 43% year-on-year but it is up by 5% since the previous quarter
Edgewise Therapeutics's debt is 99% less than its equity
Edgewise Therapeutics's equity has decreased by 20% YoY and by 6% from the previous quarter
Edgewise Therapeutics's debt has decreased by 13% YoY and by 3.8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.